Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  Akt/ERK inhibitor ONC201
Find trials that include:  Any drugs shown
Results 1-6 of 6 for your search:
Start Over
ONC201 in Treating Patients with Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0731, NCI-2015-00504, 1-907936-1, 1159166, 1-910469-1, 20152152, 204710, NCT02392572
Akt/ERK Inhibitor ONC201 in Treating Patients with Relapsed or Refractory Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma, or Transformed Large Cell Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0630, NCI-2015-00706, 204666, 1-909048-1, 20152142, 1159132, NCT02420795
Oral ONC201 in Adult Recurrent Glioblastoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 0005, NCI-2016-01031, NCT02525692
Akt/ERK Inhibitor ONC201 in Treating Patients with Advanced Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 051403, NCI-2014-01305, NCT02250781
Continuation of Akt/ERK Inhibitor ONC201 in Treating Patients with Advanced Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 051407, NCI-2014-02043, NCT02324621
Akt/ERK Inhibitor ONC201 in Treating Patients with Advanced Solid Tumors or Multiple Myeloma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PH-077, NCI-2015-02228, 15-1009, NCT02609230
Start Over